2026 Q3 - tulosraportti
UUTTA
1 päivä sitten
‧47 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
NimiOsuus
DNB Fund Disrpt Opps A EUR Acc
2,15%Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 19.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 9.11. | ||
2026 Q2 - tulosraportti 5.8. | ||
2026 Q1 - tulosraportti 11.5. | ||
2025 Q4 - tulosraportti 24.2. | ||
2025 Q3 - tulosraportti 6.11.2025 |
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·12 t sittenGood luck today everyone. Remember, this requires a bit of patience. Think everyone who holds and does not sell will be very happy by the end of next year.
·29.10.When should one buy
If you are long-term, you start topping up a bit every now and then. I have started since 2.7, most recently 13.3. Do not think it goes below 11.4 again. It can go 10X in 3-5 years. If you are not informed, read drill's comments below and you will understand the potential.- ·17.10. · MuokattuAbCellera: new senior roles — construction is moving forward I have started five companies. We never recruited without a plan: expansion, improvement, or future earnings. Senior personnel are expensive and hard to land — no management builds an executive layer without knowing what it will carry. The news: over the past ~3 weeks, from late September to mid-October, a wave of senior recruitment hit AbCellera. And the point lies in which roles: Head of Quality Assurance, Director/Senior Director QC, Director QA Validation, Head of Process Development (CMC), and Head of CMC Portfolio Management. Layer by layer: QC core (June) → operations and translational science (July) → VP Medical Affairs (Sept) → now senior quality and CMC management (Oct). Each step is higher up the value chain than the last. My reading: a company does not build a complete senior management layer for quality and manufacturing without internally counting on a product to manufacture and sell. Following the positive Phase 2 this summer, this is no longer about hope, but about realization. The direction is clear — forward. Caveat: Phase 3 and approval remain — that is where the final yes-word falls. The dates for the roles are approximate and may be refreshes, so read them as direction, not exact accounting... My interpretation of public data, not financial advice.
- ·12.10.Another giant – UBS sets a price target on AbCellera! UBS initiated coverage today (12/10) with Buy and a price target of 18 USD. Previously, JP Morgan (29/9, Overweight, 17 USD) and Goldman Sachs (24/9, Neutral, 13 USD) have started following the company. My interpretation: it is confirmation that ABCL has gone from a speculative small-cap to a name that institutions take seriously. But it says more about who can and wants to own the stock now than whether ABCL635 succeeds. The clinical risk (dose selection, phase 3) is the same. Why now? Major banks rarely cover companies valued around 1 billion USD, because their clients cannot build positions there. With a market cap of just over 4 billion USD and millions of shares in daily trading, it becomes justified. It opens the door for funds that have not looked at the company previously. Furthermore, JPM, GS and UBS reach generalist funds and global managers that Jones, Benchmark and Bloom Burton do not reach. Over time, this can broaden the ownership base and improve liquidity – but it is an opportunity, not a guarantee. Worth knowing: JPM and UBS participated as banks in the August offering. As I see it: a clear step up in status. The platform is the engine/value, ABCL635 the proof.
- ·6.10.The valuation of some biotech companies is starting to get high without them delivering profits. Profits that may only come in a few years. I have faith in BiologixAI going forward, but is this going a bit too fast in the short term? Is a correction coming soon?This exact company has several partners so they bring in money in another way. 2 good deals recently, more may come.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q3 - tulosraportti
UUTTA
1 päivä sitten
‧47 min
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·12 t sittenGood luck today everyone. Remember, this requires a bit of patience. Think everyone who holds and does not sell will be very happy by the end of next year.
- ·29.10.When should one buyIf you are long-term, you start topping up a bit every now and then. I have started since 2.7, most recently 13.3. Do not think it goes below 11.4 again. It can go 10X in 3-5 years. If you are not informed, read drill's comments below and you will understand the potential.
- ·17.10. · MuokattuAbCellera: new senior roles — construction is moving forward I have started five companies. We never recruited without a plan: expansion, improvement, or future earnings. Senior personnel are expensive and hard to land — no management builds an executive layer without knowing what it will carry. The news: over the past ~3 weeks, from late September to mid-October, a wave of senior recruitment hit AbCellera. And the point lies in which roles: Head of Quality Assurance, Director/Senior Director QC, Director QA Validation, Head of Process Development (CMC), and Head of CMC Portfolio Management. Layer by layer: QC core (June) → operations and translational science (July) → VP Medical Affairs (Sept) → now senior quality and CMC management (Oct). Each step is higher up the value chain than the last. My reading: a company does not build a complete senior management layer for quality and manufacturing without internally counting on a product to manufacture and sell. Following the positive Phase 2 this summer, this is no longer about hope, but about realization. The direction is clear — forward. Caveat: Phase 3 and approval remain — that is where the final yes-word falls. The dates for the roles are approximate and may be refreshes, so read them as direction, not exact accounting... My interpretation of public data, not financial advice.
- ·12.10.Another giant – UBS sets a price target on AbCellera! UBS initiated coverage today (12/10) with Buy and a price target of 18 USD. Previously, JP Morgan (29/9, Overweight, 17 USD) and Goldman Sachs (24/9, Neutral, 13 USD) have started following the company. My interpretation: it is confirmation that ABCL has gone from a speculative small-cap to a name that institutions take seriously. But it says more about who can and wants to own the stock now than whether ABCL635 succeeds. The clinical risk (dose selection, phase 3) is the same. Why now? Major banks rarely cover companies valued around 1 billion USD, because their clients cannot build positions there. With a market cap of just over 4 billion USD and millions of shares in daily trading, it becomes justified. It opens the door for funds that have not looked at the company previously. Furthermore, JPM, GS and UBS reach generalist funds and global managers that Jones, Benchmark and Bloom Burton do not reach. Over time, this can broaden the ownership base and improve liquidity – but it is an opportunity, not a guarantee. Worth knowing: JPM and UBS participated as banks in the August offering. As I see it: a clear step up in status. The platform is the engine/value, ABCL635 the proof.
- ·6.10.The valuation of some biotech companies is starting to get high without them delivering profits. Profits that may only come in a few years. I have faith in BiologixAI going forward, but is this going a bit too fast in the short term? Is a correction coming soon?This exact company has several partners so they bring in money in another way. 2 good deals recently, more may come.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
NimiOsuus
DNB Fund Disrpt Opps A EUR Acc
2,15%Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 19.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 9.11. | ||
2026 Q2 - tulosraportti 5.8. | ||
2026 Q1 - tulosraportti 11.5. | ||
2025 Q4 - tulosraportti 24.2. | ||
2025 Q3 - tulosraportti 6.11.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q3 - tulosraportti
UUTTA
1 päivä sitten
‧47 min
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 19.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 9.11. | ||
2026 Q2 - tulosraportti 5.8. | ||
2026 Q1 - tulosraportti 11.5. | ||
2025 Q4 - tulosraportti 24.2. | ||
2025 Q3 - tulosraportti 6.11.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·12 t sittenGood luck today everyone. Remember, this requires a bit of patience. Think everyone who holds and does not sell will be very happy by the end of next year.
- ·29.10.When should one buyIf you are long-term, you start topping up a bit every now and then. I have started since 2.7, most recently 13.3. Do not think it goes below 11.4 again. It can go 10X in 3-5 years. If you are not informed, read drill's comments below and you will understand the potential.
- ·17.10. · MuokattuAbCellera: new senior roles — construction is moving forward I have started five companies. We never recruited without a plan: expansion, improvement, or future earnings. Senior personnel are expensive and hard to land — no management builds an executive layer without knowing what it will carry. The news: over the past ~3 weeks, from late September to mid-October, a wave of senior recruitment hit AbCellera. And the point lies in which roles: Head of Quality Assurance, Director/Senior Director QC, Director QA Validation, Head of Process Development (CMC), and Head of CMC Portfolio Management. Layer by layer: QC core (June) → operations and translational science (July) → VP Medical Affairs (Sept) → now senior quality and CMC management (Oct). Each step is higher up the value chain than the last. My reading: a company does not build a complete senior management layer for quality and manufacturing without internally counting on a product to manufacture and sell. Following the positive Phase 2 this summer, this is no longer about hope, but about realization. The direction is clear — forward. Caveat: Phase 3 and approval remain — that is where the final yes-word falls. The dates for the roles are approximate and may be refreshes, so read them as direction, not exact accounting... My interpretation of public data, not financial advice.
- ·12.10.Another giant – UBS sets a price target on AbCellera! UBS initiated coverage today (12/10) with Buy and a price target of 18 USD. Previously, JP Morgan (29/9, Overweight, 17 USD) and Goldman Sachs (24/9, Neutral, 13 USD) have started following the company. My interpretation: it is confirmation that ABCL has gone from a speculative small-cap to a name that institutions take seriously. But it says more about who can and wants to own the stock now than whether ABCL635 succeeds. The clinical risk (dose selection, phase 3) is the same. Why now? Major banks rarely cover companies valued around 1 billion USD, because their clients cannot build positions there. With a market cap of just over 4 billion USD and millions of shares in daily trading, it becomes justified. It opens the door for funds that have not looked at the company previously. Furthermore, JPM, GS and UBS reach generalist funds and global managers that Jones, Benchmark and Bloom Burton do not reach. Over time, this can broaden the ownership base and improve liquidity – but it is an opportunity, not a guarantee. Worth knowing: JPM and UBS participated as banks in the August offering. As I see it: a clear step up in status. The platform is the engine/value, ABCL635 the proof.
- ·6.10.The valuation of some biotech companies is starting to get high without them delivering profits. Profits that may only come in a few years. I have faith in BiologixAI going forward, but is this going a bit too fast in the short term? Is a correction coming soon?This exact company has several partners so they bring in money in another way. 2 good deals recently, more may come.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
NimiOsuus
DNB Fund Disrpt Opps A EUR Acc
2,15%Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt